Oruka Therapeutics has reported promising results for its long-acting injectable treatment for plaque psoriasis, ORKA-001, which achieved complete skin clearance in 63% of patients during a mid-stage trial. If these results are confirmed in late-stage trials, the drug could offer a new treatment option with fewer injections compared to existing therapies.
Oruka Therapeutics' ORKA-001, a long-acting injectable treatment for plaque psoriasis, has shown promising results in a mid-stage trial with 63% of patients achieving complete skin clearance. If these results are confirmed in late-stage trials and the once-per-year dosing is feasible, this drug could become a significant new treatment option, potentially matching or surpassing current blockbusters like Skyrizi and Bimzelx with fewer injections, making it a compelling candidate for investment and monitoring in the pharmaceutical sector.